Pall (PLL) was upgraded today by analysts at EVA Dimensions, LLC and the stock is now at $32.09, down $0.26 (-0.8%) on volume of 421,756 shares traded. EVA Dimensions, LLC upgraded the sto...(Click the story link or go to http://www.marketintelligencecenter.com for the full story)
Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Pall (NYSE: PLL) closed yesterday at $32.34. So far the stock has hit a 52-week low of $18.20 and 52-week high of $34.54. Pall stock has been showing support around 31.27 and resistance in the 32.99 ran...(Click the story link or go to http://www.marketintelligencecenter.com for the full story)
Millipore Corp. (MIL) reported third-quarter earnings per share of 71 cents, well below the Zacks Consensus Estimate of 93 cents per share.
Revenues for the third quarter grew 4% from the previous year, totaling $412 million. Excluding a 3% unfavorable impact from changes in foreign currency, Millipore generated organic revenue growth of 7%. On a divisional [...]
Millipore Corp. (MIL) reported third-quarter earnings per share of 71 cents, well below the Zacks Consensus Estimate of 93 cents per share.
Revenues for the third quarter grew 4% from the previous year, totaling $412 million. Excluding a 3% unfavorable impact from changes in foreign currency, Millipore generated organic revenue growth of 7%. On a divisional basis, excluding changes in foreign currency, Millipore’s Bioprocess Division generated organic revenue growth of 8%, while the company’s Bioscience Division generated organic revenue growth of 4% from the previous year. In the Americas, revenue grew by 4% year over year while Asia recorded a 16% growth in revenues when compared to a similar period.
Bioprocess Division is sustaining its strong momentum and generating very attractive growth. The division’s performance has returned to tracking the strong fundamentals of the biotech industry and there was also an additional benefit of an increase in vaccine productions.
The company continues to increase its R&D spending in the third quarter and it is improving its innovation capabilities. Higher growth and profitability gives it the opportunity to invest while the general market is in a downturn. This investment will benefit its competitive position over time. The company completed the acquisition of BioAnaLab to extend the Company’s biopharmaceutical services offering to the European market.
Cash and equivalents were $190 million with long-term debt at $907 million and shareowner’s equity was at $1.4 billion.
It generated approximately $112 million of free cash flow, representing 74 % growth over the third quarter of 2008. It also paid down $57 million of borrowings under the company’s $678 million primary revolving credit facility, leaving approximately $14 million drawn against it at the end of the quarter.
Millipore is a life science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, it collaborates with customers to confront the world's challenging human health issues. From research to development to production, its scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. The company was founded in 1954 and is headquartered in Billerica, Massachusetts. Major competitors of the company include Pall Corp. (PLL).
HGSI - Human Genome Sciences, Inc. – Shares of the biopharmaceutical company made a miraculous recovery since yesterday’s slaughter by exploding 13.25% higher during the session to $20.40. Traders populated various contracts with bullish plays after HGSI was raised to ‘overweight’ from ‘neutral’ with a 12-month target share price of $25.00 at JPMorgan. Heavy call volume in the November contract was likely driven by traders anticipating results of Phase 3 trials employed to evaluate the efficacy of HGSI’s potential drug treatment for lupus, Benlysta. Trading at the November 20/25/30 strike prices mimicked the butterfly spread strategy, and suggests perhaps that traders expect shares to rise to $25.00 by expiration. Investors bought at least 3,500 calls at the November 20 strike for 1.88 apiece as well as purchased 3,500 calls at the November 30 strike for 60 cents each. These contracts effectively mimic the wings of the spread while the 9,000 calls sold at the central November 25 strike perhaps represent the body of the spread. Call spreads were initiated in both the December and January contracts. The December transaction, for example, involved the purchase of 1,000 calls at the December 25 strike for 2.60 each, spread against the sale of 1,000 calls at the higher December 30 strike for 1.00 apiece. The net cost of the trade amounts to 1.60 per contract. Thus, the investor may accumulate maximum potential profits of 3.40 per contract if shares of HGSI rally up to $30.00 by expiration day in December.
MSTR - Microstrategy, Inc. – The software company appeared on our ‘hot by options volume’ market scanner this afternoon due to bullish options activity. Investors initiated optimistic plays on the stock despite the 1% decline in shares to $73.03. Profit-taking action appeared in the January 2010 contract while fresh positions were taken in the April 2010 contract. It looks like one investor originally purchased 3,600 calls at the now in-the-money January 70 strike for an average premium of between 3.00 to 3.50 per contract back on July 31, 2009. Today the trader sold the calls for a whopping 7.20 apiece. Net profits enjoyed on the closing sale amount to a minimum of 3.70 up to 4.20 each. Thus, total potential profits earned by the trader are anywhere from $1,332,000 to $1,512,000. In the April contract a bullish risk reversal suggests investors expect…
All News |
Breaking News |
Featured Stories